Northern Trust Corp Purchases 145,387 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Northern Trust Corp boosted its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 6.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,575,075 shares of the biotechnology company’s stock after buying an additional 145,387 shares during the period. Northern Trust Corp owned approximately 1.09% of ADMA Biologics worth $44,163,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ADMA. Vanguard Group Inc. boosted its position in shares of ADMA Biologics by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company’s stock valued at $312,109,000 after acquiring an additional 80,302 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of ADMA Biologics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company’s stock worth $93,187,000 after buying an additional 50,399 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of ADMA Biologics by 16.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company’s stock worth $80,065,000 after buying an additional 643,661 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of ADMA Biologics by 2.8% during the 4th quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company’s stock valued at $64,654,000 after buying an additional 102,692 shares in the last quarter. Finally, Perpetual Ltd purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at about $62,300,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

ADMA has been the topic of several analyst reports. Raymond James boosted their price objective on ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a research note on Thursday. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $21.20 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a market capitalization of $5.04 billion, a P/E ratio of 75.71 and a beta of 0.57. ADMA Biologics, Inc. has a 1-year low of $6.84 and a 1-year high of $25.67. The company’s 50-day moving average is $20.17 and its 200 day moving average is $18.69.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $114.80 million during the quarter, compared to analysts’ expectations of $116.40 million. During the same quarter in the previous year, the company posted $0.08 earnings per share. The company’s quarterly revenue was up 40.2% compared to the same quarter last year. Research analysts forecast that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.